CDNA (Biotech) Stock Valuation & Fair Value Significantly overvalued
CDNA (Biotech) trades at a current P/E of 63.7, about 129% above its historical normal valuation, with a forward growth estimate of 28.1% and a PEG of 2.27. Analysts' one-year estimates have been hit 18% of the time. Priced at its historical normal P/E of 27.8 on the same blended earnings, the 2026-10-23 close of $69.21 corresponds to about $30.20 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
Valuation flags
- Overvalued by 129%
- Misses analyst estimates often (80%)
Frequently asked questions
Is CDNA overvalued?
At a current P/E of 63.7 versus its historical normal P/E of 27.8, CDNA trades about 129% above its typical valuation, with a PEG of 2.27 on 28.1% forward growth. tickerseer currently rates it significantly overvalued.
What is CDNA's fair value and PEG?
CDNA trades at a current P/E of 63.7 against a historical normal P/E of 27.8, a PEG of 2.27, and a forward growth estimate of 28.1%. Priced at its historical normal P/E of 27.8 on the same blended earnings, the 2026-10-23 close of $69.21 corresponds to about $30.20 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of CDNA changed?
tickerseer's rating has been significantly overvalued since 2026-10-24.
Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.